KR101061256B1 - 7-amino-3-vinyl-cephalosporate hydrate having a novel crystalline form and preparation method thereof - Google Patents

Abstract

The present invention relates to a 7-amino-3-vinyl-cephalosporinate hydrate having a new crystalline form and a method for preparing the same. Specifically, in the X-ray diffraction pattern of Cu target radiation, the characteristic peak represented by 2θ is 8.98 ± 0.3, It relates to a 7-amino-3-vinyl-cephalosporinate hydrate having a new crystal form appearing in 18.06 ± 0.3, 28.95 ± 0.3, 32.32 ± 0.3, 33.76 ± 0.3 and 34.40 ± 0.3 and a method for preparing the same. According to the present invention, a new crystalline 7-AVCA hydrate of high purity and high efficiency using a cross-linked Enzyme Crystal-Penicilline G Amidase / Acylase enzyme, which is easy to handle and stable in the deprotection step of an amino group protecting group, is prepared. Since it can be synthesized industrially, it can be usefully used when developing cephalosporin-based antibiotics using the 7-AVCA as an intermediate.

7-AVCA, 7-amino-3-vinyl-cephalosporinic acid, crystalline hydrate, syntha CLEC-PA enzyme, cepadinir

Description

7-Amino-3-vinyl-cephalosporinic salt hydrate having a new crystal form and preparation method

The present invention relates to a 7-amino-3-vinyl-cephalosporinate hydrate having a new crystalline form and a process for preparing the same.

Cephalosporin antibiotics are widely used to treat diseases caused by pathogenic bacteria in humans and animals, especially in the treatment of diseases caused by bacteria that are resistant to other antibiotics, such as penicillin compounds, and in the treatment of penicillin-sensitive patients. useful. In many cases, it is desirable to use antibiotics that are active against both Gram-positive and Gram-negative microorganisms, and thus, studies on the development of various types of cephalosporin antibiotics have been continued.

7-Amino-3-Vinyl-Cephalosporinic Acid (hereinafter referred to as 7-AVCA) is a representative third-generation cephalosporin-based antibiotic Cefdinir (trade name: Omnicef) having a broad antibacterial activity. And the key intermediate compounds used in the manufacture of Cefixim (trade name: Suprax). The 7-AVCA is mainly present as a hydrate, as shown in the following formula (1).

(In Formula 1, x is 3 to 6)

At this time, the Cefdinir has excellent antimicrobial activity against a wide range of pathogens, and because of its excellent stability in vivo, it is one of the third generation cephaic antibiotics attracting attention. Efficacy in microorganisms (Serratia spp., Etc.), which show efficacy, and especially drug resistance, is a popular cepha antibiotic that sells for $ 230 million in the US market in 2005.

Therefore, the preparation of 7-AVCA, which is used as an intermediate in the preparation of cephalosporin antibiotics, exhibits high stability because it affects the purity and yield of the cephalosporin antibiotics. Manufacturing AVCA is very important.

In general, the preparation of 7-AVCA is shown in Scheme 1 below,

Removing the protecting group of the carboxyl group and the protecting group of the amino group in the compound of formula (2).

In this case, phenyl or cresol is used to remove the carboxyl protecting group, and phosphorus pentachloride, pyridine or the like is used to remove the amino group protecting group. However, contaminants used to remove the amino group protecting group, pyridine and the like are harmful to the human body because they are toxic solvents of strong acids or strong bases, cause environmental pollution, and produce a lot of by-products, resulting in a decrease in yield.

Therefore, in order to solve the above problem, a method of introducing an enzyme capable of removing the amino protecting group has been devised, and penicillysiase or penicyriamidase has been used as the enzyme. The enzymes are environmentally friendly because they can react with water and can be reused.

However, there is still a need for a new 7-AVCA manufacturing method which is highly stable, reproducible and in situ, environmentally friendly, and has high yield and purity.

On the other hand, the crystalline compound contains little residual solvent in any form, such as dissolved state, and further purification effect can be obtained by crystallization. In addition, it exhibits a high stability in the manufacture of the drug, there is an advantage that it is easy to handle in the manufacturing plant.

Such crystalline compounds can generally exhibit their properties by X-ray diffraction (XRD). The XRD is a very useful means to reveal the internal microstructure of the material. Crystals in which atoms are arranged regularly scatter strongly in a specific direction as a result of scattering X-rays caused by atoms, and the crystal structure can be detected by measuring them. At this time, the XRD peak is detected at 2θ value, and when a wide XRD peak at any given position is detected at any 2θ value, it means that the peak is at 2θ value ± 0.3.

Accordingly, the present inventors, while studying to prepare crystalline 7-AVCA, using the Syntha CLEC-PA enzyme, high stability, reproducibility and in situ, yield and purity of the new crystal form 7- AVCA was prepared and the present invention was completed.

It is an object of the present invention to provide a novel crystalline 7-AVCA having high stability, high reproducibility and in situ, and high yield and purity.

Another object of the present invention is to provide a method for preparing the new crystalline 7-AVCA.

Another object of the present invention to provide a Syntha CLEC-PA enzyme used in the preparation of the new crystalline 7-AVCA.

In order to achieve the above object, the present invention has high yield and purity, and in the X-ray diffraction pattern of Cu target radiation, the characteristic peaks represented by 2θ are 8.98 ± 0.3, 18.06 ± 0.3, 28.95 ± 0.3, 32.32 ± 0.3, 33.76 ± 0.3 And new crystalline 7-AVCA appearing at 34.40 ± 0.3.

The present invention also provides a method for preparing the new crystalline 7-AVCA.

Furthermore, the present invention provides a Syntha CLEC-PA enzyme used in the preparation of the new crystalline 7-AVCA.

According to the present invention, a new crystalline 7-AVCA hydrate of high purity and high efficiency can be industrially synthesized by using a synta CLEC-PA enzyme which is easy to handle and stable in the deprotection step of an amino group protecting group, thereby producing 7-AVCA. It can be useful when developing cephalosporin antibiotics used as intermediates.

EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.

The present invention provides a new crystalline 7-amino-3-vinyl-cephalosporinate hydrate represented by the following formula (1).

[Formula 1]

(In Formula 1, x is 3 to 6)

A crystal is a solid material with an arrangement in which all of its constituent atoms, molecules, or ions are aligned in three dimensions. Crystals of the organic drug compound belong to the molecular lattice, but different crystals are produced when the process conditions are different. Furthermore, different crystals of the same drug have markedly different appearance, solubility, melting point, density, solubility and bioactivity and affect their stability and bioactivity. In this regard, the study of drug crystalline forms in the development and review of new drugs, the manufacture and quality control of drugs, and the design of new drug final formulations has become an essential and important aspect.

The 7-AVCA hydrate according to the present invention was confirmed by X-ray diffraction (XRD) measurement to be in a different crystalline form than the existing 7-AVCA. Specifically, the X-ray diffraction pattern of the 7-AVCA hydrate of the present invention showed characteristic peaks represented by 2θ at about 8.98, about 18.06, about 28.95, about 32.32, about 33.76 and about 34.40 (see FIG. 4 ). At this time, the XRD peak means 2θ ± 0.3.

The present invention also provides a process for preparing the new crystalline 7-amino-3-vinyl-cephalosporinate hydrate.

The new crystalline 7-AVCA hydrate according to the present invention

deprotecting the protecting group of the carboxyl group by adding cresol or phenol to p-methoxybenzyl-7-phenylacetamido-3-vinyl-3-cepem-4-carboxylate (2) and stirring (step 1);

Deprotecting the protecting group of the amino group by adding and stirring the synta CLEC-PA enzyme while adjusting the pH with a base (step 2);

Controlling pH with inorganic acid to crystallize deprotected 7-AVCA (step 3); And

After dissolving the aqueous solution of methanol and base in 7-AVCA produced in step 3 and dissolving, acid is added to prepare a crystalline 7-AVCA hydrate (step 4).

First, step 1 is to add a cresol or phenol to p-methoxybenzyl-7-phenylacetamido-3-vinyl-3-cepem-4-carboxylate (2) to stir to deprotect the protecting group of the carboxyl group Step.

In the production method according to the present invention, p-methoxybenzyl-7-phenylacetamido-3-vinyl-3-cefe-4-carboxylate of formula 2 is prepared or commercially available by the method of the prior art The amount of cresol or phenol to be added may be used in an appropriate amount such that the protecting group of the carboxyl group may be deprotected.

Next, step 2 is a step of deprotecting the protecting group of the amino group by adding a Cinta CLEC-PA enzyme while stirring the pH to the base to the compound in which the protecting group of the carboxyl group is deprotected in step 1.

In the production method according to the invention, the base used is an alkali metal carbonate such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate; Alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; ammonia; Trialkylamines, such as trimethylamine, etc. are mentioned.

In the production method according to the invention, the pH is preferably maintained to 7.5 ~ 8.0.

In the production method according to the present invention, since the Cinta CLEC-PA enzyme is in free or crystallized form as shown in FIG . 1 , it is easy to handle and has high reaction efficiency, and thus may be industrially useful. The synta CLEC-PA enzyme is derived from E. coli. The amount of the enzyme varies depending on the type of enzyme, substrate, reaction, temperature, equilibrium point, reaction concentration, etc., but in this reaction, it is preferable to use 0.01-20 g for 1 g of substrate. The syntha CLEC-PA enzyme can be reused in the same reaction after filtration.

Next, step 3 is a step of crystallizing the 7-AVCA by adjusting the pH with an inorganic acid to the deprotected 7-AVCA compound in the protecting group of the carboxyl group and the amino group in step 2.

In the production method according to the present invention, any inorganic acid can be used without limitation so long as it does not interfere with the crystallization of 7-AVCA. Examples thereof include hydrochloric acid, nitric acid, sulfuric acid, and the like.

In the production method according to the invention, the pH is preferably maintained at 1.5 ~ 2.5.

Next, step 4 is a step of preparing a crystalline 7-AVCA hydrate of Formula 1 by dissolving the aqueous solution of methanol and a base in 7-AVCA produced in step 3, and then adding an acid.

In the production method according to the present invention, the methanol aqueous solution is preferably mixed in a ratio of methanol: water = 5: 1 to 1: 2, and more preferably methanol: water = 4: 1.

In the production method according to the present invention, the concentration of 7-AVCA in the aqueous methanol solution is preferably 5-20%, more preferably 10%.

In the production method according to the invention, the base may be used sodium carbonate, potassium carbonate, sodium hydrogen carbonate and the like.

In the production method according to the present invention, the acid may be hydrochloric acid, sulfuric acid, nitric acid and the like.

After acid treatment in step 4, crystalline 7-AVCA hydrate is formed by filtration, washing and drying. Crystalline 7-AVCA hydrate prepared by the above method showed an XRD peak as shown in Figure 4 and Table 1, the yield was up to 93%, the purity was also 99%.

Furthermore, the present invention provides a Syntha CLEC-PA enzyme used in the preparation of the new crystalline 7-AVCA hydrate.

The CLEC-PA synthase enzyme is easy to handle because it is a glass or crystallized form as shown in Fig.

In addition, the Cinta CLEC-PA enzyme was shown to shorten the reaction time by 1 to 4 hours and improve the yield by about 10% in the deprotection experiment of the amino group protecting group (see Table 2). ).

Therefore, the Cinta CLEC-PA enzyme has high reaction efficiency, is easy to handle, and does not require a toxic organic solvent and thus is environmentally friendly, and thus can be used industrially in the preparation of crystalline 7-AVCA hydrate.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are merely to illustrate the content of the present invention is not limited to the scope of the invention.

< Example  1> New Crystallinity 7- AVCA  Preparation of Luggage

Steps 1-3: 7-amino-3-vinyl-3- Sepem -4- Carboxylic acid (7- AVCA)  Produce

p-methoxybenzyl-7-phenylacetamido-3-vinyl-3-cepem-4-carboxylate (2, 100 g, 0.215 mol) was added to 300 mL of cresol and stirred at 35-40 ° C overnight. After confirming the reaction by TLC, 1 L of ethyl acetate was added, followed by slowly adding an aqueous sodium bicarbonate solution (solution of 50 g of sodium bicarbonate in 1.5 L of water), followed by stirring at room temperature for 30 minutes. Next, ethyl acetate (500) was used to remove the cresol from the aqueous solution layer. mL) twice. After separating the water layer 10,000 units of synta CLEC-PA enzyme was added, and the mixture was stirred for 3 hours while maintaining the pH of 7.5-8.0 using a sodium bicarbonate solution at 25-30 ℃. After confirming the reaction by TLC, the enzyme was filtered and separated. Carbon complex call was added to the water layer, and the mixture was stirred for 1 hour and then filtered. 1 L of methanol was added and the pH was adjusted to 3 with 2N-HCl to produce a white solid. The solid was filtered, washed with distilled water and acetone and dried to obtain the target compound (44.7 g, yield 92%).

¹ H-NMR (D ₂ O + NaHCO ₃ , 300 MHz): δ 3.46 (d, 1H, J = 17.5 Hz), 3.60 (d, 1H, J = 17.5 Hz), 4.98 (d, 1H, J = 4.5 Hz ), 5.11 (d, 1H, J = 11.1 Hz), 5.31 (dd, 2H, J = 5.6, 4.5 Hz), 6.62 (dd, 1H, J = 11.1, 6.4 Hz).

Step 4: Crystallinity 7- AVCA  Carb Synthesis

200 mL of H ₂ O and 50 mL of MeOH were added to 10 g of 7-AVCA prepared in Step 3, 40 mL of 2N-sodium carbonate was added dropwise, and the mixture was stirred until it was completely dissolved. Thereafter, about 20-30 mL of 2N-HCl was slowly added dropwise to the reaction solution while maintaining it at room temperature to completely dissolve it, and then stirred again at room temperature for 30 minutes, filtered, washed with a small amount of acetone, and dried at 50 ° C. for 1-2 hours. Crystalline 7-AVCA hydrate was prepared.

Moisture (Karl Fischer method) 2.8%.

¹ H-NMR (D ₂ O + NaHCO ₃ , 300 MHz): δ 3.57 (d, 1H, J = 17.3 Hz), 3.75 (d, 1H, J = 17.3 Hz), 4.98 (d, 1H, J = 4.6 Hz ), 5.14 (d, 1H, J = 11.1 Hz), 5.38 (dd, 2H, J = 5.8, 4.5 Hz), 6.70 (dd, 1H, J = 11.1, 6.4 Hz).

< Comparative example >

Steps 1 to 3

7-AVCA was prepared in the same manner as in Example except that penicillin-G amidase was used instead of the synta CLEC-PA enzyme.

<Analysis>

7-AVCA and 7-AVCA hydrates prepared in Examples and Comparative Examples were analyzed using XRD and microscope.

As a result of measurement by XRD, 7-AVCA compounds of Examples and Comparative Examples showed peaks as shown in FIGS . 2 and 3 , respectively, and 7-AVCA hydrate showed peaks as shown in FIG. 4 . Specific values of the 7-AVCA hydrate XRD are shown in Table 1 below.

No. 2θ d I / I ₀ One 8.98 9.8394 71 2 18.06 4.9078 53 3 23.22 3.9974 8 4 27.75 3.2110 18 5 28.95 3.0806 92 6 30.32 2.9455 100 7 32.30 2.7693 15 8 33.76 2.6528 71 9 34.40 2.6049 83 10 35.70 2.5129 11 11 36.66 2.4493 25 12 36.96 2.4301 13 13 39.88 2.2567 40 14 43.98 2.0571 12 15 44.28 2.0439 22 16 44.60 2.0300 48 17 45.38 1.9969 19 18 46.10 1.9673 12 19 47.64 1.9073 20 20 48.22 1.8857 8 21 51.30 1.7795 13 22 52.40 1.7447 14 23 53.16 1.7215 7 24 55.26 1.6609 19 25 56.94 1.6159 10 26 57.72 1.5959 12 27 66.02 1.4139 5 28 66.75 1.4000 6

It was found to be a new crystalline compound different from the 7-AVCA compound ( FIGS. 2 and 3 ).

In Examples and Comparative Examples, the microscopic observation results of the 7-AVCA compounds in Figure 5, showing the microscopic observation results of the 7-hydrate AVCA prepared in example in Fig.

As shown in Figs . 5 and 6 , it was confirmed that the 7-AVCA hydrate according to the present invention ( Fig. 6 ) has a larger crystal compared to the 7-AVCA compound ( Fig. 5 ).

< Experimental Example > Enzymes Deprotection  Efficiency experiment

In order to determine the deprotection efficiency according to the enzyme used in the preparation of 7-AVCA hydrate according to the present invention, the following experiment was performed.

Add 10,000 units of the Cinta CLEC-PA enzyme (Altus Biologics product) used in the examples or the penicillin amidase (Sigma product) used in the comparative examples, starting materials (p-methoxybenzyl-7-phenylacetamido-). 3-vinyl-3-cepem-4-carboxylate) was changed to 100 g, 200 g and 400 g, followed by a deprotection reaction of the amino group protecting group.

After the reaction time and the yield of the product was measured and shown in Table 2.

Amount of starting material (g) Syntha CLEC-PA Enzyme Penicillin amidase Response time (hours) yield(%) Response time (hours) yield(%) 100 3 93 4 85 200 6 91 10 81 400 12 85 18 78

As shown in Table 2, the synta CLEC-PA enzyme used in the present invention was shown to reduce the reaction time by 1 to 4 hours and improve the yield by about 10% than the penicillin amidase used as a conventional deprotection enzyme.

Therefore, the Cinta CLEC-PA enzyme has high reaction efficiency, is easy to handle, and does not require a toxic organic solvent, and thus is environmentally friendly, and thus can be industrially useful in preparing crystalline 7-AVCA hydrate.

1 is a photograph showing the crystal form of the synta CLEC-PA enzyme used in the present invention.

2 is an XRD graph of 7-AVCA according to an embodiment of the present invention.

3 is an XRD graph of 7-AVCA according to a comparative example of the present invention.

4 is an XRD graph of crystalline 7-AVCA hydrate according to one embodiment of the present invention.

5 is a micrograph of 7-AVCA according to an embodiment of the present invention.

6 is a micrograph of crystalline 7-AVCA hydrate according to one embodiment of the present invention.

Claims (13)

In the X-ray diffraction pattern of Cu target radiation, the characteristic peaks represented by 2θ are represented by the following Chemical Formula 1 with new crystal forms appearing at 8.98 ± 0.3, 18.06 ± 0.3, 28.95 ± 0.3, 32.32 ± 0.3, 33.76 ± 0.3 and 34.40 ± 0.3 7-amino-3-vinyl-cephalosporinate hydrate: [Formula 1]

. (In Formula 1, x is 3 to 6) deprotecting the protecting group of the carboxyl group by adding cresol or phenol to p-methoxybenzyl-7-phenylacetamido-3-vinyl-3-cepem-4-carboxylate (2) and stirring (step 1); Adding a Cynta CLEC-PA (Cross-Linked Enzyme Crystal-Penicilline G Amidase / Acylase) enzyme while adjusting the pH with a base to stir to deprotect the protecting group of the amino group (step 2); Controlling pH with inorganic acid to crystallize deprotected 7-AVCA (step 3); And The crystalline 7-amino- of claim 1 comprising preparing a crystalline 7-AVCA hydrate by adding an aqueous solution of methanol and a base to 7-AVCA produced in step 3 and dissolving it, and then adding an acid. Process for the preparation of 3-vinyl-cephalosporin hydrate. 3. The crystalline 7-amino-3-vinyl-cephalosporinate hydrate of claim 2, wherein the base of step 2 is selected from the group consisting of alkali metal carbonate, alkali metal hydroxide, ammonia water and trialkylamine. Manufacturing method. 4. The crystalline 7-amino according to claim 3, wherein the alkali metal carbonate is sodium carbonate, potassium carbonate or sodium hydrogen carbonate, the alkali metal hydroxide is sodium or potassium hydroxide, and the trialkylamine is trimethylamine. Process for the preparation of 3-vinyl-cephalosporinate hydrate. The method of claim 2, wherein the pH of the step 2 is maintained at 7.5 to 8.0 crystalline 7-amino-3-vinyl-cephalosporinate hydrate. The method of claim 2, wherein the inorganic acid of step 3 is hydrochloric acid, nitric acid or sulfuric acid. The method of claim 2, wherein the pH of the step 3 is maintained at 1.5 to 2.5 crystalline 7-amino-3-vinyl-cephalosporinate hydrate. The crystalline 7-amino-3-vinyl-cephalosporinate hydrate of claim 2, wherein the aqueous methanol solution of step 4 is mixed at a ratio of methanol: water = 5: 1 to 1: 2. Way. The method of claim 2, wherein the concentration of 7-AVCA in the aqueous methanol solution of step 4 is 5 to 20% of the crystalline 7-amino-3-vinyl-cephalosporinate hydrate. The method of claim 2, wherein the base of step 4 is selected from the group consisting of sodium carbonate, potassium carbonate and sodium hydrogen carbonate. The method of claim 2, wherein the acid of step 4 is hydrochloric acid, sulfuric acid or nitric acid. delete delete

Images